Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Do Hedge Funds and Insiders Love Allergan, Inc. (AGN)?

Page 1 of 2

Allergan, Inc. (NYSE:AGN) was in 31 hedge funds’ portfolio at the end of the first quarter of 2013. AGN has seen a decrease in hedge fund interest in recent months. There were 31 hedge funds in our database with AGN holdings at the end of the previous quarter.

In the 21st century investor’s toolkit, there are plenty of methods shareholders can use to monitor the equity markets. Some of the most innovative are hedge fund and insider trading sentiment. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the top money managers can outperform the market by a superb amount (see just how much).

Allergan, Inc. (NYSE:AGN)Equally as important, bullish insider trading activity is a second way to break down the investments you’re interested in. Obviously, there are a number of stimuli for an upper level exec to get rid of shares of his or her company, but just one, very obvious reason why they would initiate a purchase. Various academic studies have demonstrated the impressive potential of this tactic if piggybackers understand what to do (learn more here).

With these “truths” under our belt, it’s important to take a gander at the latest action surrounding Allergan, Inc. (NYSE:AGN).

What does the smart money think about Allergan, Inc. (NYSE:AGN)?

At the end of the first quarter, a total of 31 of the hedge funds we track were long in this stock, a change of 0% from one quarter earlier. With hedgies’ positions undergoing their usual ebb and flow, there exists a select group of key hedge fund managers who were increasing their stakes considerably.

When looking at the hedgies we track, Robert Pohly’s Samlyn Capital had the largest position in Allergan, Inc. (NYSE:AGN), worth close to $77.6 million, accounting for 2.4% of its total 13F portfolio. Coming in second is Jim Simons of Renaissance Technologies, with a $69.8 million position; 0.2% of its 13F portfolio is allocated to the company. Remaining hedgies that hold long positions include Roberto Mignone’s Bridger Management, Phill Gross and Robert Atchinson’s Adage Capital Management and D. E. Shaw’s D E Shaw.

Seeing as Allergan, Inc. (NYSE:AGN) has experienced declining sentiment from the aggregate hedge fund industry, it’s easy to see that there was a specific group of fund managers that elected to cut their positions entirely at the end of the first quarter. Intriguingly, Arthur B Cohen and Joseph Healey’s Healthcor Management LP dumped the largest investment of the “upper crust” of funds we key on, totaling close to $91.7 million in stock.. SAC Subsidiary’s fund, CR Intrinsic Investors, also cut its stock, about $4.6 million worth. These transactions are intriguing to say the least, as total hedge fund interest stayed the same (this is a bearish signal in our experience).

How are insiders trading Allergan, Inc. (NYSE:AGN)?

Bullish insider trading is best served when the company we’re looking at has experienced transactions within the past six months. Over the latest half-year time frame, Allergan, Inc. (NYSE:AGN) has experienced zero unique insiders buying, and 10 insider sales (see the details of insider trades here).

Let’s also review hedge fund and insider activity in other stocks similar to Allergan, Inc. (NYSE:AGN). These stocks are Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY), Pharmacyclics, Inc. (NASDAQ:PCYC), Forest Laboratories, Inc. (NYSE:FRX), Novo Nordisk A/S (ADR) (NYSE:NVO), and Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). This group of stocks are in the drug manufacturers – other industry and their market caps are similar to AGN’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!